Skip to main content

CHR Hansen Holding

Chr. Hansen Holding A/S was a Danish bioscience company headquartered in Hørsholm, north of Copenhagen, that merged into Novozymes A/S in January 2024 to create Novonesis, resulting in the delisting of its shares from Nasdaq Copenhagen. Founded in 1874 by pharmacist Christian Ditlev Ammentorp Hansen, the company grew into a leading global developer and supplier of natural ingredient solutions based on microbial cultures, enzymes, and probiotics. Its operations were organized into two primary reporting segments: Food Cultures & Enzymes, which supplied starter cultures, coagulants, and bioprotective solutions to the dairy, cheese, meat, and fermented beverage industries, and Health & Nutrition, which provided clinically documented probiotics for dietary supplements, infant formula, animal nutrition, and biological plant protection. Revenue growth was propelled by long-term formulation partnerships with global food and nutrition manufacturers, rising consumer demand for natural preservation, and expanding adoption of biological agricultural inputs. With major production facilities across Europe, North America, and South America, more than four thousand employees in over thirty countries, and roughly EUR 1.3 billion in annual revenue, Chr. Hansen was combined with Novozymes to establish a global biosolutions leader.

8 of the funds FundTelligence covers report a position in CHR Hansen Holding.

Legal name
CHR HANSEN HOLDING
Sector
Materials
Country
Denmark
Funds holding it
8
Exposure themes
Bioenergy & Renewable Fuels, Energy Production, Energy Transition

Funds holding CHR Hansen Holding

Loading...